Accutane (isotretinoin) capsules - Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER) - February 2010

There have been post-marketing reports of erythema multiforme and severe skin reactions [eg, Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN)] associated with isotretinoin use. These events may be serious and result in death, life-threatening events, hospitalization, or disability. Patients should be monitored closely for severe skin reactions, and discontinuation of Accutane should be considered if warranted.

Read more at:Accutane Lawsuit